Excision of Lymph Node Trial (EXCILYNT) (Mel69)

The purpose of this study is to find out if removing only the cancerous lymph node (known as a lymph node excision) is effective at preventing cancer from coming back in the same area of the lymph node excision. The study team is also trying to find out the side effects of this type of surgery and how much the surgery impacts quality of life. In order to be eligible for this study, participants must have been diagnosed with metastatic melanoma and have one detected cancerous lymph node by imaging (CT/PET scan) or clinical examination, and are a candidate for lymph node excision.

Trial Details

NCT ID
NCT05839912
Phase
NA
Sponsor
Craig L Slingluff, Jr
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Excision of clinically detected lymph node metastasis before any systemic therapy
  • Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • New York, New York, United States|40.71427,-74.00597
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • Provision of signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Male or female, aged 18 years or older at enrollment
  • ECOG performance status of 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →